RecruitingNCT06933134
Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis
Sponsor
University Hospital, Tours
Enrollment
30 participants
Start Date
Apr 23, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with rheumatoid arthritis (ra). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06933134
Related Trials
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
NCT071632215 locations
Gluten-Free vs Mediterranean Diet in Rheumatoid Arthritis
NCT076462621 location
Dysphagia in Rheumatoid Arthritis
NCT074017322 locations
An Investigation of the Effect of Smartphone Usage Levels on Cervical Posture, Tongue Pressure, Balance, and Neck Disability in Individuals With Rheumatoid Arthritis and Ankylosing Spondylitis
NCT076275421 location
Desloratadine as Adjunct Therapy for Rheumatoid Arthritis
NCT076328721 location